Table 1.
Current clinical trials involving immune checkpoint blockade in human glioma.
| Clinical trial | Title of the study | Study population | Phase | Intervention | Study design | Date |
|---|---|---|---|---|---|---|
| NCT01670890 | Efficacy and Safety of TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas | Malignant Gliomas | Phase I | Drug: Temozolomide Drug: Temozolomide plus neoadjuvant CDDP |
Allocation: Non-Randomized Intervention Model: Parallel Masking: None (Open Label). Primary Purpose: Treatment Assignment |
August 2012 |
| NCT03011671 | Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma | Malignant Glioma of Brain | Phase I | Drug: Acetazolamide and Tolomozomide | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | October 3, 2018 |
| NCT03973879 | Combination of PVSRIPO and Atezolizumab for Adults With Recurrent Malignant Glioma | Malignant Glioma | Phase I Phase II |
Biological: PVSRIPO Drug: Atezolizumab |
Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
February 2020 |
| NCT00953121 | Bevacizumab Plus Irinotecan Plus Carboplatin for Recurrent Malignant Glioma (MG) | Malignant Glioma | Phase II | Drug: bevacizumab and CPT-11 and Carboplatin | •Allocation: NonRandomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
September 2009 |
| NCT02313272 | Hypofractionated Stereotactic Irradiation (HFSRT) With Pembrolizumab and Bevacizumab for Recurrent High Grade Gliomas | Malignant Glioma | Phase I | Radiation: Hypofractionated Stereotactic Irradiation (HFSRT) Drug: Pembrolizumab Drug: Bevacizumab |
Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
May 5, 2015 |
| NCT02829931 | Hypofractionated Stereotactic Irradiation With Nivolumab, Ipilimumab and Bevacizumab in Patients With Recurrent High Grade Gliomas | Malignant Glioma | Phase I | Radiation: Hypofractionated Stereotactic Irradiation Drug: Nivolumab Drug: Bevacizumab Drug: Ipilimumab |
Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
August 22, 2016 |
| NCT01891747 | A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma | Malignant Glioma | Phase I | Drug: Bevacizumab Drug: Temozolomide Dietary Supplement: Vitamin C |
Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
July 2013 |
| NCT00271609 | Bevacizumab for Recurrent Malignant Glioma | Recurrent High-Grade Gliomas Malignant Gliomas |
Phase II | Drug: Bevacizumab | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
December 2005 |
| NCT02590263 | Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma | Malignant Glioma Glioblastoma Multiforme |
Phase I Phase II |
Radiation: Whole Brain Radiation Drug: Temozolomide Drug: ABT-414 |
Allocation: NonRandomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
August 24, 2015 |
| NCT00782756 | Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant Glioma | Brain Cancer Malignant Glioma |
Phase II | Other: radiotherapy (RT) in combination with temozolomide and bevacizumab | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
October 28, 2008 |
| NCT01738646 | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | Recurrent Glioblastoma Multiforme Malignant Glioma Adult Brain Tumor |
Phase II | Drug: Vorinostat Drug: Bevacizumab |
Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment |
January 2013 |